[Plasma levels and the antihypertensive effect of the preparation celiprolol].
The antihypertensive activity of the new cardioselective adrenergic blocker celiprolol in hypertonic disease, stage I-II, according to WHO as compared with the preparation acebutolol was assessed under the conditions of double blind study. Thirty patients with arterial hypertension were included in the study if after one week placebo period, met the criteria for inclusion. Blood samples from each patient, were collected for the determination of plasma concentrations of celiprolol before the beginning, by 2, 15 and 29 day of the treatment, 24 hour after the last intake and before the following intake. At the same time, each patient was subjected to complete physical and clinical-laboratory investigation. At a level of significance 99%, celiprolol and acebutolol reduced the systolic and diastolic arterial blood pressure to normal values by the end of the second and fourth week without any statistically significant difference between their antihypertensive activity. No significant difference was established between the values of blood pressure, recorded by the end of second and fourth week, in the patients treated with celiprolol and acebutolol. The analysis of the dependence of the reduced diastolic blood pressure on the value of plasma celiprolol concentration by the end of 14-day dose interval established a significant negative correlation (r = -0.737, p less than 0.1). The reduction of systolic blood pressure does not correlate with statistical significance, with the plasma levels of the preparation. The results from the study revealed that the preparations celiprolol and acebutolol have equivalent therapeutic effectiveness in the treatment of hypertonic disease, stage I-II according to WHO.(ABSTRACT TRUNCATED AT 250 WORDS)